Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PROC | P04070 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1782571 | 0.98 | MME (0.33) | MMEITGB3ITGA2BF2PROC | |
| Water SCHEMBL6244439 | 0.97 | MME (0.32) | MMEITGB3ITGA2B | |
| SCHEMBL22529222 | 0.93 | CYP4F2 (0.31) | ITGB3ITGA2BCYP4F2CYP4A11 | |
| SCHEMBL6676794 | 0.88 | MAPT (0.37) | ITGB3ITGA2B | |
| SCHEMBL3525418 | 0.84 | CA12 (0.42) | CYP4F2CYP4A11NPSR1 | |
| SCHEMBL7437999 | 0.79 | MAPT (0.38) | CYP4F2CYP4A11NPSR1 | |
| SCHEMBL1696853 | 0.78 | CA12 (0.41) | CYP4F2CYP4A11 | |
| SCHEMBL7431988 | 0.78 | MAPT (0.40) | CYP4F2CYP4A11NPSR1 | |
| SCHEMBL5227332 | 0.75 | NPSR1 (0.33) | CYP4F2CYP4A11NPSR1 | |
| SCHEMBL27175299 | 0.75 | CTSL (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6806279-B2 | FOR THERAPY OF AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS, UVEITIS, AND PSORIASIS, ALLOGRAFT REJECTION, AND GRAFT-VERSUS-HOST DISEASE | SUNESIS PHARMACEUTICALS, INC. | 2004-10-19 | — | — | US | disclosed |
| CN-1150206-C | Bradykinin antagonist peptides containing N-substituted glycines | — | 2004-05-19 | — | — | CN | disclosed |
| US-20030149049-A1 | Small-molecule inhibitors of interleukin-2 | SUNESIS PHARMACEUTICALS, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003051797-A2 | SMALL-MOLECULE INHIBITORS OF INTERLEUKIN-2 | SUNESIS PHARMACEUTICALS, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| US-5700779-A | ALLEVIATING PAIN, ASTHMA, INFLAMMATION, CEREBRAL EDEMA, CARDIOVASCULAR DYSFUNCTION | CORTECH, INC. (US) | 1997-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149049-A1 | Small-molecule inhibitors of interleukin-2 | IL2, IL2RA, HLA-DRB1 | MME 1639/4885ITGB3 2700/4885ITGA2B 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.